Bio-Rad Laboratories (BIO) Net Margin (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Net Margin for 18 consecutive years, with 57.05% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin rose 828.0% year-over-year to 57.05% in Q2 2026; TTM through Jun 2026 was 8.59%, a 391.0% decrease from a year earlier, with the FY2025 full-year figure at 29.42%, up 10127.0% from the prior year.
• Net Margin was 57.05% for Q2 2026 at Bio-Rad Laboratories, up from 89.02% in the prior quarter.
• Over five years, Net Margin peaked at 113.35% in Q4 2022 and troughed at 480.98% in Q1 2022.
• A 5-year average of 45.64% and a median of 10.56% in 2025 frame the typical range for Net Margin.
• Across the five-year window, Net Margin slumped 61546 bps in 2022 and soared 49117 bps in 2023, its largest moves.
• Over 5 years, Net Margin stood at 113.35% in 2022, then tumbled by 55 bps to 51.34% in 2023, then slumped by 309 bps to 107.24% in 2024, then soared by 197 bps to 103.87% in 2025, then slumped by 45 bps to 57.05% in 2026.
• The last three Net Margin figures came in at 57.05% (Q2 2026), 89.02% (Q1 2026), and 103.87% (Q4 2025), per Business Quant data.